A Food and Drug Administration advisory panel issued a negative assessment of Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) Duchenne muscular dystrophy treatment eteplirsen. Shares of the biopharmaceutical plummeted $17.50 to $14.13.
Negative assessment of Sarepta's eteplirsen
January 15, 2016 at 12:21 PM EST
